Fig. 7

Inhibition of S100A9 combined with anti-PD-1 therapy enhances anti-tumor response in vivo. a Schematic representation of the murine experimental workflow. b Weight curves and (c) tumor volume over time (n = 6 mice per group). d Number of CD3⁺ T cells, CD4⁺ T cells (e), CD8⁺ T cells (f), and GranzymB⁺CD8⁺ T cells (g) per gram of hepa1-6 tumor. h Schematic representation of the combination therapy workflow. i Weight curves and tumor volume (j) over time (n = 5–6 mice per group). k Tumor weight and pictures (l) of hepa1-6 tumors from four groups of mice (n = 5–6 mice per group). Scale bar, 1 cm. m Tumor growth curves of individual mice. i.g.: intragastric administration. q.d., once daily. i.p.: intraperitoneal injection. Data are represented as mean ± S.E.M. P values in (c and j) were determined by 2-way ANOVA.P values in (d and e) were determined using Mann–whitney U-test. P values in (f and g) were determined using two-tailed unpaired Student’s t-tests. P value in k was determined by one-way ANOVA. *P < 0.05, **P < 0·01, ***P < 0.001 and ****P < 0.0001